| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | transmembrane transporter activity | SLC6A2 SLC6A4 CACNA1B OTOP1 CACNA1E SLC15A5 SLC6A11 KCNK13 SLC16A9 P2RX5 SLC16A1 SLC44A3 SLC9B2 | 2.80e-09 | 1180 | 29 | 13 | GO:0022857 |
| GeneOntologyMolecularFunction | transporter activity | SLC6A2 SLC6A4 CACNA1B OTOP1 CACNA1E SLC15A5 SLC6A11 KCNK13 SLC16A9 P2RX5 SLC16A1 SLC44A3 SLC9B2 | 8.16e-09 | 1289 | 29 | 13 | GO:0005215 |
| GeneOntologyMolecularFunction | monoatomic cation transmembrane transporter activity | SLC6A2 SLC6A4 CACNA1B OTOP1 CACNA1E SLC6A11 KCNK13 P2RX5 SLC16A1 SLC9B2 | 1.75e-08 | 664 | 29 | 10 | GO:0008324 |
| GeneOntologyMolecularFunction | symporter activity | 6.69e-08 | 150 | 29 | 6 | GO:0015293 | |
| GeneOntologyMolecularFunction | monoatomic ion transmembrane transporter activity | SLC6A2 SLC6A4 CACNA1B OTOP1 CACNA1E SLC6A11 KCNK13 P2RX5 SLC16A1 SLC9B2 | 9.30e-08 | 793 | 29 | 10 | GO:0015075 |
| GeneOntologyMolecularFunction | inorganic cation transmembrane transporter activity | SLC6A2 SLC6A4 CACNA1B OTOP1 CACNA1E SLC6A11 KCNK13 SLC16A1 SLC9B2 | 1.60e-07 | 627 | 29 | 9 | GO:0022890 |
| GeneOntologyMolecularFunction | secondary active transmembrane transporter activity | 1.73e-07 | 296 | 29 | 7 | GO:0015291 | |
| GeneOntologyMolecularFunction | inorganic molecular entity transmembrane transporter activity | SLC6A2 SLC6A4 CACNA1B OTOP1 CACNA1E SLC6A11 KCNK13 SLC16A1 SLC9B2 | 7.89e-07 | 758 | 29 | 9 | GO:0015318 |
| GeneOntologyMolecularFunction | sodium:chloride symporter activity | 1.85e-06 | 17 | 29 | 3 | GO:0015378 | |
| GeneOntologyMolecularFunction | monoatomic anion:sodium symporter activity | 2.63e-06 | 19 | 29 | 3 | GO:0015373 | |
| GeneOntologyMolecularFunction | metal ion transmembrane transporter activity | 3.55e-06 | 465 | 29 | 7 | GO:0046873 | |
| GeneOntologyMolecularFunction | active transmembrane transporter activity | 4.20e-06 | 477 | 29 | 7 | GO:0022804 | |
| GeneOntologyMolecularFunction | chloride:monoatomic cation symporter activity | 4.78e-06 | 23 | 29 | 3 | GO:0015377 | |
| GeneOntologyMolecularFunction | monoatomic anion:monoatomic cation symporter activity | 7.00e-06 | 26 | 29 | 3 | GO:0015296 | |
| GeneOntologyMolecularFunction | monoatomic cation channel activity | 8.37e-06 | 343 | 29 | 6 | GO:0005261 | |
| GeneOntologyMolecularFunction | solute:monoatomic cation symporter activity | 2.54e-05 | 119 | 29 | 4 | GO:0015294 | |
| GeneOntologyMolecularFunction | monoatomic ion channel activity | 4.33e-05 | 459 | 29 | 6 | GO:0005216 | |
| GeneOntologyMolecularFunction | monoatomic anion transmembrane transporter activity | 6.44e-05 | 151 | 29 | 4 | GO:0008509 | |
| GeneOntologyMolecularFunction | active monoatomic ion transmembrane transporter activity | 6.64e-05 | 301 | 29 | 5 | GO:0022853 | |
| GeneOntologyMolecularFunction | voltage-gated calcium channel activity involved in regulation of cytosolic calcium levels | 7.29e-05 | 9 | 29 | 2 | GO:0099511 | |
| GeneOntologyMolecularFunction | voltage-gated calcium channel activity involved in regulation of presynaptic cytosolic calcium levels | 7.29e-05 | 9 | 29 | 2 | GO:0099626 | |
| GeneOntologyMolecularFunction | channel activity | 9.11e-05 | 525 | 29 | 6 | GO:0015267 | |
| GeneOntologyMolecularFunction | passive transmembrane transporter activity | 9.21e-05 | 526 | 29 | 6 | GO:0022803 | |
| GeneOntologyMolecularFunction | sodium ion transmembrane transporter activity | 1.04e-04 | 171 | 29 | 4 | GO:0015081 | |
| GeneOntologyMolecularFunction | voltage-gated monoatomic ion channel activity | 1.33e-04 | 182 | 29 | 4 | GO:0005244 | |
| GeneOntologyMolecularFunction | monoamine transmembrane transporter activity | 1.33e-04 | 12 | 29 | 2 | GO:0008504 | |
| GeneOntologyMolecularFunction | voltage-gated channel activity | 1.38e-04 | 184 | 29 | 4 | GO:0022832 | |
| GeneOntologyMolecularFunction | organic hydroxy compound transmembrane transporter activity | 1.41e-04 | 70 | 29 | 3 | GO:1901618 | |
| GeneOntologyMolecularFunction | high voltage-gated calcium channel activity | 1.83e-04 | 14 | 29 | 2 | GO:0008331 | |
| GeneOntologyMolecularFunction | solute:sodium symporter activity | 2.18e-04 | 81 | 29 | 3 | GO:0015370 | |
| GeneOntologyMolecularFunction | organic cation transmembrane transporter activity | 2.34e-04 | 83 | 29 | 3 | GO:0015101 | |
| GeneOntologyMolecularFunction | monocarboxylic acid transmembrane transporter activity | 2.97e-04 | 90 | 29 | 3 | GO:0008028 | |
| GeneOntologyMolecularFunction | secondary active monocarboxylate transmembrane transporter activity | 3.43e-04 | 19 | 29 | 2 | GO:0015355 | |
| GeneOntologyMolecularFunction | neurotransmitter transmembrane transporter activity | 4.20e-04 | 21 | 29 | 2 | GO:0005326 | |
| GeneOntologyMolecularFunction | chloride transmembrane transporter activity | 7.77e-04 | 125 | 29 | 3 | GO:0015108 | |
| GeneOntologyMolecularFunction | gated channel activity | 1.31e-03 | 334 | 29 | 4 | GO:0022836 | |
| GeneOntologyMolecularFunction | voltage-gated monoatomic cation channel activity | 1.37e-03 | 152 | 29 | 3 | GO:0022843 | |
| GeneOntologyMolecularFunction | inorganic anion transmembrane transporter activity | 1.91e-03 | 171 | 29 | 3 | GO:0015103 | |
| GeneOntologyMolecularFunction | voltage-gated calcium channel activity | 2.03e-03 | 46 | 29 | 2 | GO:0005245 | |
| GeneOntologyMolecularFunction | proton transmembrane transporter activity | 2.51e-03 | 188 | 29 | 3 | GO:0015078 | |
| GeneOntologyMolecularFunction | carboxylic acid transmembrane transporter activity | 3.29e-03 | 207 | 29 | 3 | GO:0046943 | |
| GeneOntologyMolecularFunction | organic acid transmembrane transporter activity | 3.33e-03 | 208 | 29 | 3 | GO:0005342 | |
| GeneOntologyMolecularFunction | organic anion transmembrane transporter activity | 8.62e-03 | 293 | 29 | 3 | GO:0008514 | |
| GeneOntologyMolecularFunction | calcium channel activity | 1.50e-02 | 129 | 29 | 2 | GO:0005262 | |
| GeneOntologyMolecularFunction | antiporter activity | 1.70e-02 | 138 | 29 | 2 | GO:0015297 | |
| GeneOntologyMolecularFunction | calcium ion transmembrane transporter activity | 2.02e-02 | 151 | 29 | 2 | GO:0015085 | |
| GeneOntologyBiologicalProcess | inorganic cation transmembrane transport | SLC6A2 SLC6A4 CACNA1B OTOP1 CACNA1E SLC6A11 KCNK13 P2RX5 SLC16A1 SLC9B2 | 1.91e-07 | 922 | 28 | 10 | GO:0098662 |
| GeneOntologyBiologicalProcess | monoatomic cation transmembrane transport | SLC6A2 SLC6A4 CACNA1B OTOP1 CACNA1E SLC6A11 KCNK13 P2RX5 SLC16A1 SLC9B2 | 2.33e-07 | 942 | 28 | 10 | GO:0098655 |
| GeneOntologyBiologicalProcess | inorganic ion transmembrane transport | SLC6A2 SLC6A4 CACNA1B OTOP1 CACNA1E SLC6A11 KCNK13 P2RX5 SLC16A1 SLC9B2 | 4.73e-07 | 1017 | 28 | 10 | GO:0098660 |
| GeneOntologyBiologicalProcess | monoatomic ion transmembrane transport | SLC6A2 SLC6A4 CACNA1B OTOP1 CACNA1E SLC6A11 KCNK13 P2RX5 SLC16A1 SLC9B2 | 1.10e-06 | 1115 | 28 | 10 | GO:0034220 |
| GeneOntologyBiologicalProcess | monoatomic cation transport | SLC6A2 SLC6A4 CACNA1B OTOP1 CACNA1E SLC6A11 KCNK13 P2RX5 SLC16A1 SLC9B2 | 1.54e-06 | 1157 | 28 | 10 | GO:0006812 |
| GeneOntologyBiologicalProcess | monoatomic ion transport | SLC6A2 SLC6A4 CACNA1B OTOP1 CACNA1E SLC6A11 KCNK13 P2RX5 SLC16A1 SLC9B2 | 7.21e-06 | 1374 | 28 | 10 | GO:0006811 |
| GeneOntologyBiologicalProcess | neurotransmitter reuptake | 1.83e-05 | 38 | 28 | 3 | GO:0098810 | |
| GeneOntologyBiologicalProcess | neurotransmitter transport | 2.33e-05 | 259 | 28 | 5 | GO:0006836 | |
| GeneOntologyBiologicalProcess | calcium ion import across plasma membrane | 3.72e-05 | 48 | 28 | 3 | GO:0098703 | |
| GeneOntologyBiologicalProcess | calcium ion import into cytosol | 3.72e-05 | 48 | 28 | 3 | GO:1902656 | |
| GeneOntologyBiologicalProcess | metal ion transport | 3.87e-05 | 1000 | 28 | 8 | GO:0030001 | |
| GeneOntologyBiologicalProcess | response to pain | 4.47e-05 | 51 | 28 | 3 | GO:0048265 | |
| GeneOntologyBiologicalProcess | neurotransmitter uptake | 4.74e-05 | 52 | 28 | 3 | GO:0001504 | |
| GeneOntologyBiologicalProcess | import into cell | 6.43e-05 | 1074 | 28 | 8 | GO:0098657 | |
| GeneOntologyBiologicalProcess | glucose homeostasis | 8.27e-05 | 338 | 28 | 5 | GO:0042593 | |
| GeneOntologyBiologicalProcess | carbohydrate homeostasis | 8.39e-05 | 339 | 28 | 5 | GO:0033500 | |
| GeneOntologyBiologicalProcess | sodium ion transmembrane transport | 1.70e-04 | 208 | 28 | 4 | GO:0035725 | |
| GeneOntologyBiologicalProcess | calcium ion import | 3.13e-04 | 98 | 28 | 3 | GO:0070509 | |
| GeneOntologyBiologicalProcess | osteoclast development | 4.04e-04 | 22 | 28 | 2 | GO:0036035 | |
| GeneOntologyBiologicalProcess | bone cell development | 4.04e-04 | 22 | 28 | 2 | GO:0098751 | |
| GeneOntologyBiologicalProcess | sodium ion transport | 4.92e-04 | 275 | 28 | 4 | GO:0006814 | |
| GeneOntologyBiologicalProcess | type II interferon-mediated signaling pathway | 6.11e-04 | 27 | 28 | 2 | GO:0060333 | |
| GeneOntologyBiologicalProcess | multicellular organismal response to stress | 6.52e-04 | 126 | 28 | 3 | GO:0033555 | |
| GeneOntologyBiologicalProcess | inorganic ion import across plasma membrane | 9.23e-04 | 142 | 28 | 3 | GO:0099587 | |
| GeneOntologyBiologicalProcess | inorganic cation import across plasma membrane | 9.23e-04 | 142 | 28 | 3 | GO:0098659 | |
| GeneOntologyBiologicalProcess | organic cation transport | 9.80e-04 | 145 | 28 | 3 | GO:0015695 | |
| GeneOntologyBiologicalProcess | synaptic transmission, dopaminergic | 1.03e-03 | 35 | 28 | 2 | GO:0001963 | |
| GeneOntologyBiologicalProcess | peptide transport | 1.27e-03 | 355 | 28 | 4 | GO:0015833 | |
| GeneOntologyBiologicalProcess | osteoclast differentiation | 1.35e-03 | 162 | 28 | 3 | GO:0030316 | |
| GeneOntologyBiologicalProcess | organic acid transmembrane transport | 1.47e-03 | 167 | 28 | 3 | GO:1903825 | |
| GeneOntologyBiologicalProcess | proton transmembrane transport | 1.55e-03 | 170 | 28 | 3 | GO:1902600 | |
| GeneOntologyBiologicalProcess | signal release | 1.68e-03 | 653 | 28 | 5 | GO:0023061 | |
| GeneOntologyCellularComponent | presynaptic membrane | 4.81e-04 | 277 | 28 | 4 | GO:0042734 | |
| GeneOntologyCellularComponent | presynapse | 9.64e-04 | 886 | 28 | 6 | GO:0098793 | |
| GeneOntologyCellularComponent | cytoplasmic vesicle membrane | 1.36e-03 | 1307 | 28 | 7 | GO:0030659 | |
| GeneOntologyCellularComponent | vesicle membrane | 1.47e-03 | 1325 | 28 | 7 | GO:0012506 | |
| GeneOntologyCellularComponent | voltage-gated calcium channel complex | 1.73e-03 | 46 | 28 | 2 | GO:0005891 | |
| Domain | NA_NEUROTRAN_SYMP_2 | 2.43e-06 | 18 | 28 | 3 | PS00754 | |
| Domain | SNF | 2.88e-06 | 19 | 28 | 3 | PF00209 | |
| Domain | NA_NEUROTRAN_SYMP_3 | 2.88e-06 | 19 | 28 | 3 | PS50267 | |
| Domain | Na/ntran_symport | 2.88e-06 | 19 | 28 | 3 | IPR000175 | |
| Domain | NA_NEUROTRAN_SYMP_1 | 2.88e-06 | 19 | 28 | 3 | PS00610 | |
| Domain | Ca_chan_IQ | 4.53e-05 | 7 | 28 | 2 | PF08763 | |
| Domain | GPHH | 4.53e-05 | 7 | 28 | 2 | PF16905 | |
| Domain | GPHH_dom | 4.53e-05 | 7 | 28 | 2 | IPR031649 | |
| Domain | VDCC_a1su_IQ | 4.53e-05 | 7 | 28 | 2 | IPR014873 | |
| Domain | Ca_chan_IQ | 4.53e-05 | 7 | 28 | 2 | SM01062 | |
| Domain | VDCCAlpha1 | 9.68e-05 | 10 | 28 | 2 | IPR002077 | |
| Domain | AdipoR/HlyIII-related | 1.18e-04 | 11 | 28 | 2 | IPR004254 | |
| Domain | HlyIII | 1.18e-04 | 11 | 28 | 2 | PF03006 | |
| Domain | MFS_dom | 1.04e-03 | 134 | 28 | 3 | IPR020846 | |
| Domain | fn3 | 1.79e-03 | 162 | 28 | 3 | PF00041 | |
| Domain | FN3 | 2.61e-03 | 185 | 28 | 3 | SM00060 | |
| Domain | FN3 | 3.21e-03 | 199 | 28 | 3 | PS50853 | |
| Domain | Channel_four-helix_dom | 3.29e-03 | 57 | 28 | 2 | IPR027359 | |
| Domain | - | 3.29e-03 | 57 | 28 | 2 | 1.20.120.350 | |
| Domain | FN3_dom | 3.68e-03 | 209 | 28 | 3 | IPR003961 | |
| Domain | MFS | 5.92e-03 | 77 | 28 | 2 | IPR011701 | |
| Domain | MFS_1 | 5.92e-03 | 77 | 28 | 2 | PF07690 | |
| Domain | MFS | 1.14e-02 | 108 | 28 | 2 | PS50850 | |
| Domain | Ion_trans_dom | 1.26e-02 | 114 | 28 | 2 | IPR005821 | |
| Domain | Ion_trans | 1.26e-02 | 114 | 28 | 2 | PF00520 | |
| Pathway | REACTOME_TRANSPORT_OF_BILE_SALTS_AND_ORGANIC_ACIDS_METAL_IONS_AND_AMINE_COMPOUNDS | 4.35e-06 | 76 | 21 | 4 | MM15072 | |
| Pathway | REACTOME_TRANSPORT_OF_BILE_SALTS_AND_ORGANIC_ACIDS_METAL_IONS_AND_AMINE_COMPOUNDS | 6.50e-06 | 84 | 21 | 4 | M27334 | |
| Pathway | WP_NRF2_PATHWAY | 5.03e-05 | 141 | 21 | 4 | M39454 | |
| Pathway | REACTOME_NEURONAL_SYSTEM | 1.09e-04 | 335 | 21 | 5 | MM14503 | |
| Pathway | KEGG_MEDICUS_REFERENCE_CA2_CAM_VGCC_RYR_SIGNALING_PATHWAY | 1.15e-04 | 11 | 21 | 2 | M47958 | |
| Pathway | REACTOME_PRESYNAPTIC_DEPOLARIZATION_AND_CALCIUM_CHANNEL_OPENING | 1.15e-04 | 11 | 21 | 2 | MM14498 | |
| Pathway | REACTOME_PRESYNAPTIC_DEPOLARIZATION_AND_CALCIUM_CHANNEL_OPENING | 1.15e-04 | 11 | 21 | 2 | M26913 | |
| Pathway | REACTOME_TRANSMISSION_ACROSS_CHEMICAL_SYNAPSES | 2.39e-04 | 211 | 21 | 4 | MM14502 | |
| Pathway | REACTOME_NEURONAL_SYSTEM | 2.84e-04 | 411 | 21 | 5 | M735 | |
| Pathway | REACTOME_NA_CL_DEPENDENT_NEUROTRANSMITTER_TRANSPORTERS | 3.56e-04 | 19 | 21 | 2 | MM15107 | |
| Pathway | REACTOME_NA_CL_DEPENDENT_NEUROTRANSMITTER_TRANSPORTERS | 3.56e-04 | 19 | 21 | 2 | M27362 | |
| Pathway | REACTOME_TRANSPORT_OF_SMALL_MOLECULES | 3.61e-04 | 681 | 21 | 6 | MM14985 | |
| Pathway | REACTOME_SLC_MEDIATED_TRANSMEMBRANE_TRANSPORT | 3.78e-04 | 238 | 21 | 4 | MM15076 | |
| Pathway | REACTOME_SLC_MEDIATED_TRANSMEMBRANE_TRANSPORT | 4.49e-04 | 249 | 21 | 4 | M5988 | |
| Pathway | KEGG_MEDICUS_REFERENCE_VGCC_CA2_APOPTOTIC_PATHWAY | 5.25e-04 | 23 | 21 | 2 | M47666 | |
| Pathway | REACTOME_TRANSPORT_OF_SMALL_MOLECULES | 5.48e-04 | 736 | 21 | 6 | M27287 | |
| Pathway | REACTOME_TRANSMISSION_ACROSS_CHEMICAL_SYNAPSES | 6.09e-04 | 270 | 21 | 4 | M15514 | |
| Pathway | KEGG_MEDICUS_REFERENCE_CA2_ENTRY_VOLTAGE_GATED_CA2_CHANNEL | 6.21e-04 | 25 | 21 | 2 | M47948 | |
| Pathway | WP_MONOAMINE_TRANSPORT | 1.02e-03 | 32 | 21 | 2 | M39724 | |
| Pathway | WP_NUCLEAR_RECEPTORS_METAPATHWAY | 1.07e-03 | 314 | 21 | 4 | M39428 | |
| Pathway | KEGG_TYPE_II_DIABETES_MELLITUS | 2.19e-03 | 47 | 21 | 2 | M19708 | |
| Pathway | KEGG_CALCIUM_SIGNALING_PATHWAY | 2.23e-03 | 178 | 21 | 3 | M2890 | |
| Pathway | WP_SYNAPTIC_VESICLE_PATHWAY | 2.58e-03 | 51 | 21 | 2 | M39457 | |
| Pathway | KEGG_LEISHMANIA_INFECTION | 5.07e-03 | 72 | 21 | 2 | M3126 | |
| Pathway | REACTOME_INTEGRATION_OF_ENERGY_METABOLISM | 5.07e-03 | 72 | 21 | 2 | MM14631 | |
| Pathway | WP_DRAVET_SYNDROME_SCN1AA1783V_POINT_MUTATION_MODEL | 5.21e-03 | 73 | 21 | 2 | MM16641 | |
| Pubmed | 6.71e-07 | 2 | 29 | 2 | 25295552 | ||
| Pubmed | 6.71e-07 | 2 | 29 | 2 | 15337646 | ||
| Pubmed | 6.71e-07 | 2 | 29 | 2 | 20017301 | ||
| Pubmed | 6.71e-07 | 2 | 29 | 2 | 25650523 | ||
| Pubmed | 6.71e-07 | 2 | 29 | 2 | 15610184 | ||
| Pubmed | 6.71e-07 | 2 | 29 | 2 | 19468717 | ||
| Pubmed | Effects of ablation of N- and R-type Ca(2+) channels on pain transmission. | 6.71e-07 | 2 | 29 | 2 | 12074836 | |
| Pubmed | Norepinephrine and serotonin transporter genes: impact on treatment response in depression. | 6.71e-07 | 2 | 29 | 2 | 20588071 | |
| Pubmed | 6.71e-07 | 2 | 29 | 2 | 21129446 | ||
| Pubmed | 6.71e-07 | 2 | 29 | 2 | 18511195 | ||
| Pubmed | Effects of duloxetine on norepinephrine and serotonin transporter activity in healthy subjects. | 6.71e-07 | 2 | 29 | 2 | 24346757 | |
| Pubmed | 6.71e-07 | 2 | 29 | 2 | 23086945 | ||
| Pubmed | 6.71e-07 | 2 | 29 | 2 | 20491280 | ||
| Pubmed | The repertoire of solute carriers of family 6: identification of new human and rodent genes. | 6.86e-07 | 21 | 29 | 3 | 16125675 | |
| Pubmed | 2.01e-06 | 3 | 29 | 2 | 12401330 | ||
| Pubmed | 2.01e-06 | 3 | 29 | 2 | 38996073 | ||
| Pubmed | 2.01e-06 | 3 | 29 | 2 | 19482066 | ||
| Pubmed | 2.01e-06 | 3 | 29 | 2 | 19649213 | ||
| Pubmed | 2.01e-06 | 3 | 29 | 2 | 20332182 | ||
| Pubmed | Distinct roles for Cav2.1-2.3 in activity-dependent synaptic dynamics. | 2.01e-06 | 3 | 29 | 2 | 24523520 | |
| Pubmed | Cellular expression of the monocarboxylate transporter (MCT) family in the placenta of mice. | 2.01e-06 | 3 | 29 | 2 | 20022372 | |
| Pubmed | 2.01e-06 | 3 | 29 | 2 | 15138209 | ||
| Pubmed | Serotonin transporter gene and adverse life events in adult ADHD. | 2.01e-06 | 3 | 29 | 2 | 18214863 | |
| Pubmed | Synapse and Active Zone Assembly in the Absence of Presynaptic Ca2+ Channels and Ca2+ Entry. | 4.02e-06 | 4 | 29 | 2 | 32616470 | |
| Pubmed | Cerebellar granule cell signaling is indispensable for normal motor performance. | 4.02e-06 | 4 | 29 | 2 | 37141091 | |
| Pubmed | 4.02e-06 | 4 | 29 | 2 | 18937309 | ||
| Pubmed | 4.02e-06 | 4 | 29 | 2 | 11343649 | ||
| Pubmed | 4.02e-06 | 4 | 29 | 2 | 16848906 | ||
| Pubmed | 6.70e-06 | 5 | 29 | 2 | 8825650 | ||
| Pubmed | 6.70e-06 | 5 | 29 | 2 | 11296258 | ||
| Pubmed | 6.70e-06 | 5 | 29 | 2 | 15451373 | ||
| Pubmed | Effect of genetic polymorphisms on smoking cessation: a trial of bupropion in Korean male smokers. | 6.70e-06 | 5 | 29 | 2 | 18197080 | |
| Pubmed | An action potential initiation mechanism in distal axons for the control of dopamine release. | 1.00e-05 | 6 | 29 | 2 | 35324301 | |
| Pubmed | 1.00e-05 | 6 | 29 | 2 | 9238069 | ||
| Pubmed | 1.00e-05 | 6 | 29 | 2 | 20858707 | ||
| Pubmed | Expression and immunolocalization of the plasma membrane monoamine transporter in the brain. | 1.00e-05 | 6 | 29 | 2 | 17408864 | |
| Pubmed | Alpha-neurexins couple Ca2+ channels to synaptic vesicle exocytosis. | 1.00e-05 | 6 | 29 | 2 | 12827191 | |
| Pubmed | A candidate gene analysis of methylphenidate response in attention-deficit/hyperactivity disorder. | 1.00e-05 | 6 | 29 | 2 | 19858760 | |
| Pubmed | 1.00e-05 | 6 | 29 | 2 | 15135235 | ||
| Pubmed | A transient placental source of serotonin for the fetal forebrain. | 1.41e-05 | 7 | 29 | 2 | 21512572 | |
| Pubmed | 1.41e-05 | 7 | 29 | 2 | 19844206 | ||
| Pubmed | Rebuilding essential active zone functions within a synapse. | 1.41e-05 | 7 | 29 | 2 | 35176221 | |
| Pubmed | 1.87e-05 | 8 | 29 | 2 | 28330839 | ||
| Pubmed | 1.87e-05 | 8 | 29 | 2 | 28109119 | ||
| Pubmed | 2.41e-05 | 9 | 29 | 2 | 16382099 | ||
| Pubmed | 2.41e-05 | 9 | 29 | 2 | 16024787 | ||
| Pubmed | PAQR proteins: a novel membrane receptor family defined by an ancient 7-transmembrane pass motif. | 3.68e-05 | 11 | 29 | 2 | 16044242 | |
| Pubmed | 6.07e-05 | 14 | 29 | 2 | 12739169 | ||
| Pubmed | 7.00e-05 | 15 | 29 | 2 | 19944766 | ||
| Pubmed | 7.00e-05 | 15 | 29 | 2 | 20188150 | ||
| Pubmed | 7.00e-05 | 15 | 29 | 2 | 24453333 | ||
| Pubmed | 8.00e-05 | 16 | 29 | 2 | 19693267 | ||
| Pubmed | 1.02e-04 | 18 | 29 | 2 | 19506906 | ||
| Pubmed | 1.14e-04 | 19 | 29 | 2 | 19095219 | ||
| Pubmed | Genetical genomic determinants of alcohol consumption in rats and humans. | 1.74e-04 | 130 | 29 | 3 | 19874574 | |
| Pubmed | Large-scale analysis of ion channel gene expression in the mouse heart during perinatal development. | 2.12e-04 | 139 | 29 | 3 | 16985003 | |
| Pubmed | 2.30e-04 | 143 | 29 | 3 | 20424473 | ||
| Pubmed | 2.50e-04 | 28 | 29 | 2 | 19352218 | ||
| Pubmed | Genetic associations of brain structural networks in schizophrenia: a preliminary study. | 3.08e-04 | 31 | 29 | 2 | 20691427 | |
| Pubmed | 3.28e-04 | 32 | 29 | 2 | 19320717 | ||
| Pubmed | Maternal Transient Receptor Potential Vanilloid 6 (Trpv6) Is Involved In Offspring Bone Development. | 4.63e-04 | 38 | 29 | 2 | 30786075 | |
| GeneFamily | Solute carriers | SLC6A2 SLC6A4 SLC15A5 SLC6A11 SLC16A9 SLC16A1 SLC44A3 SLC9B2 | 2.62e-08 | 395 | 24 | 8 | 752 |
| GeneFamily | Progestin and adipoQ receptor family | 9.22e-05 | 11 | 24 | 2 | 930 | |
| GeneFamily | Calcium voltage-gated channel subunits | 5.38e-04 | 26 | 24 | 2 | 253 | |
| GeneFamily | Fibronectin type III domain containing | 1.20e-03 | 160 | 24 | 3 | 555 | |
| ToppCell | LPS-IL1RA-Epithelial_alveolar-Mes-Like-Differentiating_AT2|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 5.89e-07 | 103 | 29 | 4 | eb9f008b5fb8a01df8ea4faf6e6aebc1a9db9bd3 | |
| ToppCell | kidney_cells-CKD+DKD_normotensive-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Proximal_Tubule_Epithelial_Cell_Segment_1_/_Segment_2|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 2.31e-06 | 145 | 29 | 4 | 47a3bb973a508d3097213a2d86ad1ce697af9bae | |
| ToppCell | renal_cortex_nuclei-Hypertensive_with+without-CKD-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Degenerative_Proximal_Tubule_Epithelial_Cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 4.04e-06 | 167 | 29 | 4 | 3edb0570e583bb527165bcd8a4c25a042054043b | |
| ToppCell | Control-B_cells-B_cells|Control / group, cell type (main and fine annotations) | 4.98e-06 | 176 | 29 | 4 | d2c353783bd78dc24f28e00d917b88d8294fb5df | |
| ToppCell | COVID-19_Moderate-B_memory|COVID-19_Moderate / disease group, cell group and cell class | 5.69e-06 | 182 | 29 | 4 | bbdbef62389ac062118cc0c7979686393399f2c8 | |
| ToppCell | COVID-19_Severe-B_memory|World / disease group, cell group and cell class | 6.33e-06 | 187 | 29 | 4 | f29c71f2505bb64f3010ada491d422b87a6f7db3 | |
| ToppCell | PBMC-Control-Lymphocyte-B-B_cell-B_memory|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 6.46e-06 | 188 | 29 | 4 | 9256c5f45c97df209bb9c322c3b557d4f726a333 | |
| ToppCell | PBMC-Control-Lymphocyte-B-B_cell-B_memory-B_memory-3|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 6.60e-06 | 189 | 29 | 4 | ac0203f17b481d608587113ea2de0f383b29ed27 | |
| ToppCell | 390C-Lymphocytic-B_cell-|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells) | 6.74e-06 | 190 | 29 | 4 | f63c9474f23bb72f0bb1fc531342f0da04ed8b3e | |
| ToppCell | 390C-Lymphocytic-B_cell|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells) | 6.74e-06 | 190 | 29 | 4 | 53bf211f0e8a44f5adb89c43b210a1e35120b6a8 | |
| ToppCell | PBMC-Control-Lymphocyte-B-B_cell-B_memory|Control / Location, Disease Group, Cell group, Cell class (2021.03.09) | 6.88e-06 | 191 | 29 | 4 | 03f6da73e7b706252d2096507222229c4101a27b | |
| ToppCell | PBMC-Control-Lymphocyte-B-B_cell-B_memory-|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09) | 6.88e-06 | 191 | 29 | 4 | 578b58782e816ecaeabfbc616ceb1dcd53ee428b | |
| ToppCell | COVID-19-lung-Macrophage_VCANhi_FCN1hi|lung / Disease (COVID-19 only), tissue and cell type | 7.77e-06 | 197 | 29 | 4 | a0f8a992282a6d64890f5574c7c9741fcb38dadd | |
| ToppCell | mild-B_memory|mild / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 8.09e-06 | 199 | 29 | 4 | 025bb65629d9e20c374e8f1ba08c36d1bb569190 | |
| ToppCell | Frontal_cortex-Endothelial-ENDOTHELIAL_TIP-Dcn_2-Dcn_2_2|Frontal_cortex / BrainAtlas - Mouse McCarroll V32 | 9.12e-05 | 135 | 29 | 3 | 4451c44f3ad788437f4e2ae81049fbbab53f967e | |
| ToppCell | Frontal_cortex-Endothelial-ENDOTHELIAL_TIP-Dcn_2|Frontal_cortex / BrainAtlas - Mouse McCarroll V32 | 9.12e-05 | 135 | 29 | 3 | 45f67f33c8320d9fb6dbceae603b564f6a8ffd1e | |
| ToppCell | PBMC-Control-Lymphocyte-B-B_cell-B_memory-B_memory-6|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 1.22e-04 | 149 | 29 | 3 | 2cd860b96ed4be4d26844085d464961c1418054a | |
| ToppCell | LPS-antiTNF-Hematopoietic_Mast-Mast_cells|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.22e-04 | 149 | 29 | 3 | 59aa1f2a5cbeba64c4529fb05f544db17fd8b188 | |
| ToppCell | LPS-antiTNF-Hematopoietic_Mast|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.22e-04 | 149 | 29 | 3 | 1527cdd98a2734cbf8ce4c6170557280b71c55cb | |
| ToppCell | LPS_only-Hematopoietic_Mast-Mast_cells-T-cells|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.25e-04 | 150 | 29 | 3 | ccb782fbcb3122266354a112a9a850506664f44d | |
| ToppCell | LPS_only-Hematopoietic_Mast-Mast_cells|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.25e-04 | 150 | 29 | 3 | 7290e9a812b1b2f919e67ccde0acf52687ab138f | |
| ToppCell | LPS_only-Hematopoietic_Mast|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.25e-04 | 150 | 29 | 3 | 2c5078a1f769ba8153dee756b53d28eb7b434a96 | |
| ToppCell | 10x5'-Liver-Myeloid_Mac-Intestinal_macrophages|Liver / Manually curated celltypes from each tissue | 1.40e-04 | 156 | 29 | 3 | 9a897fc79c4fae94c5f2e9012d65297f9225e5e3 | |
| ToppCell | droplet-Liver-Hepatocytes-18m-Myeloid-Kupffer_cell|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.40e-04 | 156 | 29 | 3 | d72c2f5f72d269e29033f8728d924e0d4c8772c7 | |
| ToppCell | saliva-Mild-Moderate_progression_d12-25-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c09-GZMK-FOS_l|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.59e-04 | 163 | 29 | 3 | 13f76f2979558f5cd27fbfd1659b413b3cac18f5 | |
| ToppCell | 3'-GW_trimst-1.5-LargeIntestine-Neuronal-Glial_immature-Differentiating_glia|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 1.71e-04 | 167 | 29 | 3 | 17c653b46507c8bb85da95836ae72a6015336142 | |
| ToppCell | Mid-temporal_gyrus_(MTG)-Neuronal-Glutamatergic_Excit-Glut_A_(CT)-Glut_CT2_L6_FEZF2-Exc_L6_FEZF2_SLITRK6|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 1.77e-04 | 169 | 29 | 3 | 1c9e54e7b14eb99996590fb93b257cf881a9f184 | |
| ToppCell | systemic_lupus_erythematosus-flare-Lymphocytic_NK-natural_killer_cell-male|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 1.86e-04 | 172 | 29 | 3 | 68fd03f2c8ee01fe46194400f74ede3830e00f34 | |
| ToppCell | severe-B_memory|severe / disease stage, cell group and cell class | 1.90e-04 | 173 | 29 | 3 | 3a987ac53a0136cc4c70ce8b901a15fc00c795e1 | |
| ToppCell | PND03-Epithelial-Epithelial_Airway-Neurosecretory-PNEC-PNEC_mature|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 1.96e-04 | 175 | 29 | 3 | 8362a46f5804333baa84cd56d450bc147f372a7e | |
| ToppCell | PND03-Epithelial-Epithelial_Airway-Neurosecretory-PNEC|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 1.96e-04 | 175 | 29 | 3 | 8b4c62e608f0ec84e563bbf0ebffe3ed44085298 | |
| ToppCell | severe-B_memory|World / disease stage, cell group and cell class | 2.00e-04 | 176 | 29 | 3 | 4e5c6b1aa5ffd13593a6bcd1e1253c1737c5c2b4 | |
| ToppCell | Primary_Visual_cortex_(V1C)-Neuronal-Glutamatergic_Excit-Glut_A_(CT)-Glut_CT2_L6_FEZF2-Exc_L6_FEZF2_SLITRK6|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.03e-04 | 177 | 29 | 3 | 62f180d5a487b449f715de49ee1e1e11c4e0cf4d | |
| ToppCell | 5'-GW_trimst-2-LargeIntestine-Hematopoietic-B_cells-Immature_B|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 2.06e-04 | 178 | 29 | 3 | 2e51c1596022b7047994ee13c18375bad19a54a5 | |
| ToppCell | TCGA-Adrenal-Primary_Tumor-Pheochromocytoma-Pheochromocytoma-1|TCGA-Adrenal / Sample_Type by Project: Shred V9 | 2.10e-04 | 179 | 29 | 3 | 431e1b29015ec817f778499106d24b19cfc825ae | |
| ToppCell | 5'-GW_trimst-2-LargeIntestine-Hematopoietic-B_cells|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 2.17e-04 | 181 | 29 | 3 | e7d9910f6143055645b6f03b1018282e6c215f10 | |
| ToppCell | URO-Lymphocyte-B-B_memory|URO / Disease, Lineage and Cell Type | 2.20e-04 | 182 | 29 | 3 | 8ffdf15230349ad53fe15bb467724d28c5a05bf6 | |
| ToppCell | wk_08-11-Epithelial-PNS-PCP4+_neuron|wk_08-11 / Celltypes from embryonic and fetal-stage human lung | 2.27e-04 | 184 | 29 | 3 | eac2a9089913f33a961ba11519b53645790f2056 | |
| ToppCell | droplet-Bladder-BLADDER-1m-Epithelial-luminal_bladder_epithelial_cell_(umbrella_cell)|Bladder / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.27e-04 | 184 | 29 | 3 | 382b1e90b3f437af596750669c0465a169d97095 | |
| ToppCell | PBMC-Severe-Lymphocyte-B-B_cell-B_memory-B_memory-3|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 2.31e-04 | 185 | 29 | 3 | 91c9a3ea1afd97d35bd05648875d29b35fe09128 | |
| ToppCell | PBMC-Convalescent-Lymphocyte-B-B_cell-B_memory-B_memory-3|Convalescent / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 2.31e-04 | 185 | 29 | 3 | 05e6eb78ead81268c1656e7ffe34f9cb7329b908 | |
| ToppCell | systemic_lupus_erythematosus-managed-Lymphocytic_B-B_atypical-male|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 2.31e-04 | 185 | 29 | 3 | 53960307c6710401c3d52a766c3f4704ace9637f | |
| ToppCell | 10x5'-GI_small-bowel-Lymphocytic_B|GI_small-bowel / Manually curated celltypes from each tissue | 2.35e-04 | 186 | 29 | 3 | a5c0bd4f6a7542f67d478dcdc0645ae6d927a395 | |
| ToppCell | droplet-Lung-nan-21m-Myeloid-alveolar_macrophage|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.35e-04 | 186 | 29 | 3 | 8f77e552e613b6e124443c7f6ef5c1316a5ff8db | |
| ToppCell | droplet-Lung-nan-21m-Myeloid-Alveolar_Macrophage|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.35e-04 | 186 | 29 | 3 | f1aa0c58336d23bcbe52a59e7af954d20085bdb6 | |
| ToppCell | PBMC-Convalescent-Lymphocyte-B-B_cell-B_memory-|Convalescent / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09) | 2.38e-04 | 187 | 29 | 3 | 43f81863063509337bd56a67010c62fb51109bd5 | |
| ToppCell | PBMC-Convalescent-Lymphocyte-B-B_cell-B_memory|Convalescent / Location, Disease Group, Cell group, Cell class (2021.03.09) | 2.38e-04 | 187 | 29 | 3 | ea56cfca919a09db852b7ee5e42323f822962465 | |
| ToppCell | 18-Airway-Epithelial-Club-like_secretory|Airway / Age, Tissue, Lineage and Cell class | 2.38e-04 | 187 | 29 | 3 | d1e301afcc39054ae1f867d80e564e30a137e3f8 | |
| ToppCell | 3'-GW_trimst-1-LargeIntestine-Neuronal-neurons_A-Branch_A3_(IPAN/IN)|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 2.42e-04 | 188 | 29 | 3 | bd091503f580dedab40e0996273101285d24b586 | |
| ToppCell | Multiple_Sclerosis-Lymphocyte-B-B_memory|Multiple_Sclerosis / Disease, Lineage and Cell Type | 2.42e-04 | 188 | 29 | 3 | 8da631b2c75441b7309f03e7d4c14f15f2367be6 | |
| ToppCell | Control-Lymphoid_B-B_memory|Control / Disease group, lineage and cell class | 2.42e-04 | 188 | 29 | 3 | ba4245de3bee29118abab57c4fce60b2007a189c | |
| ToppCell | PBMC-Convalescent-Lymphocyte-B-B_cell-B_memory|Convalescent / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 2.42e-04 | 188 | 29 | 3 | b6ae707b033a17c75ca81f9194631ead1b63d170 | |
| ToppCell | PBMC-Mild-Lymphocyte-B-B_cell-B_memory-B_memory-3|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 2.42e-04 | 188 | 29 | 3 | cd833a125a5279ac32a9a9cb9ecd05ae24bea3a9 | |
| ToppCell | ILEUM-non-inflamed-(2)_Memory_B_cells|non-inflamed / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2) | 2.46e-04 | 189 | 29 | 3 | 8d9b8a952db78646f137526f3175ba502f1d3692 | |
| ToppCell | remission-B_memory|remission / disease stage, cell group and cell class | 2.46e-04 | 189 | 29 | 3 | a7b434a5d2cc7c3952cb8f16d11219b691c6c2b6 | |
| ToppCell | COVID-19_Severe-Lymphoid_B-B_memory|COVID-19_Severe / Disease group, lineage and cell class | 2.50e-04 | 190 | 29 | 3 | b6510c419a15ed049c0a0a6a6697b643668741c3 | |
| ToppCell | remission-B_memory|World / disease stage, cell group and cell class | 2.50e-04 | 190 | 29 | 3 | c3f55f752e47b5a71e111367cdbed4a39ab5cb21 | |
| ToppCell | COPD-Lymphoid-T_Regulatory|Lymphoid / Disease state, Lineage and Cell class | 2.54e-04 | 191 | 29 | 3 | 3ae18bc4e3dff49b5d5958da8ebc3f747274b69c | |
| ToppCell | COVID-19_Convalescent-Lymphoid_B-B_memory|COVID-19_Convalescent / Disease group, lineage and cell class | 2.54e-04 | 191 | 29 | 3 | 4a853cd2434b0f5b18e1f853c37515845046c88b | |
| ToppCell | severe_COVID-19-B_memory|World / disease group, cell group and cell class (v2) | 2.54e-04 | 191 | 29 | 3 | 3b57e353b74ebc866d0e11deeba31fa764c42325 | |
| ToppCell | Adult-Immune-monocyte-D175|Adult / Lineage, Cell type, age group and donor | 2.54e-04 | 191 | 29 | 3 | cbebb4d9550fdcd606cb3685ac9546c6b73fd422 | |
| ToppCell | PBMC-Mild-Lymphocyte-B-B_cell-B_memory|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 2.54e-04 | 191 | 29 | 3 | 22134a2c1a92208bc1629a620ce73a56502613c2 | |
| ToppCell | PBMC-Mild-Lymphocyte-B-B_cell-B_memory-|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09) | 2.58e-04 | 192 | 29 | 3 | debd471f61cf3606b8e9c246add0be5df601af7f | |
| ToppCell | control-B_memory|control / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 2.58e-04 | 192 | 29 | 3 | d6ef271b6c4f9b49323650f3f773abd61c1b13c3 | |
| ToppCell | Adult-Immune-alveolar_macrophage_(MARCO_positive)-D175|Adult / Lineage, Cell type, age group and donor | 2.58e-04 | 192 | 29 | 3 | 733491e932350e3c216a626cc49c3cd3fe970a82 | |
| ToppCell | COVID-19_Mild-Lymphoid_B-B_memory|COVID-19_Mild / Disease group, lineage and cell class | 2.58e-04 | 192 | 29 | 3 | d27db7669de95bddbea8ccb83e6f10ae7240b1ab | |
| ToppCell | PBMC-Mild-Lymphocyte-B-B_cell-B_memory|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09) | 2.58e-04 | 192 | 29 | 3 | 314f74dd3c6d94839eed05b9a1a398217ef78029 | |
| ToppCell | moderate-Lymphoid-B_cell|Lymphoid / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls | 2.58e-04 | 192 | 29 | 3 | ae3727503c3b9f4695e565fd3161cc33b898f349 | |
| ToppCell | VE-naiveBc-|VE / Condition, Cell_class and T cell subcluster | 2.58e-04 | 192 | 29 | 3 | bca2aec4811627225fccd92abe2f3b1ba729c9ce | |
| ToppCell | VE-naiveBc|VE / Condition, Cell_class and T cell subcluster | 2.58e-04 | 192 | 29 | 3 | 87cdda9a170f6f2fa56d0ed1d3fd2f93bfe09aa1 | |
| ToppCell | renal_cortex_nuclei-Adult_normal_reference-Epithelial|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 2.62e-04 | 193 | 29 | 3 | 3866667dd221612589ae50f5c52f73a183a49ce6 | |
| ToppCell | mild_COVID-19-B_memory|World / disease group, cell group and cell class (v2) | 2.62e-04 | 193 | 29 | 3 | 69b70c838328fdc7dbb6b5449fe2811a5389a839 | |
| ToppCell | Children_(3_yrs)-Immune-monocyte-D046|Children_(3_yrs) / Lineage, Cell type, age group and donor | 2.62e-04 | 193 | 29 | 3 | 58e1930a1d80ad3729ab9604ac8ebf7308232a3d | |
| ToppCell | PBMC_fresh-frozen-Mild-Moderate_convalescent_d36-51-Lymphocytic-Lymphocytic_B-B_cell-B_c03-CD27-AIM2|Mild-Moderate_convalescent_d36-51 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 2.62e-04 | 193 | 29 | 3 | de0213f2105b814f38ffbfd004ea7603230eed68 | |
| ToppCell | mild_COVID-19-B_memory|mild_COVID-19 / disease group, cell group and cell class (v2) | 2.62e-04 | 193 | 29 | 3 | 7e6fe70928a50b0a8f12220e572c07c5670d092e | |
| ToppCell | CF-Lymphoid-B_cell|Lymphoid / Disease state, Lineage and Cell class | 2.62e-04 | 193 | 29 | 3 | 7ebf20344a9a154fd2cffa281526867fcf0aded3 | |
| ToppCell | renal_cortex_nuclei-Hypertensive_with+without-CKD-Epithelial|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 2.62e-04 | 193 | 29 | 3 | 82e8a4c40299ffcdfd5a0da711bb9de6fb8a2eaa | |
| ToppCell | severe-B_cell|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 2.66e-04 | 194 | 29 | 3 | 2fee6083fb56b16d1f04fd0b92ec622fd26ba3fa | |
| ToppCell | critical-Lymphoid-B_cell|Lymphoid / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls | 2.66e-04 | 194 | 29 | 3 | eeae611ab72d602fb545c729a14ef38ce5c47f2c | |
| ToppCell | 3'-Child09-12-SmallIntestine-Hematopoietic-B_cells-Naive_B|Child09-12 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 2.70e-04 | 195 | 29 | 3 | f00e6d000e107daed68d3ffa8948e1f6a41eb242 | |
| ToppCell | 10x5'-lymph-node_spleen-Lymphocytic_B-Memory_B_cells|lymph-node_spleen / Manually curated celltypes from each tissue | 2.70e-04 | 195 | 29 | 3 | 8b307079cee67fc1df55277d0cab21ea4b97e552 | |
| ToppCell | Bronchial_Biopsy-Immune-Luminal_Macrophages|Immune / Tissue, Lineage and Cell class of Lung Cells from 10X | 2.70e-04 | 195 | 29 | 3 | 6800c17026ec6c56132bf4664b8fcd74d7836579 | |
| ToppCell | COVID-19-lung-Macrophage_CD163hi_MERTKhi|lung / Disease (COVID-19 only), tissue and cell type | 2.70e-04 | 195 | 29 | 3 | 148fff8c3c9ba45ec36e98dff1be57e3f8294506 | |
| ToppCell | Children_(3_yrs)-Immune-monocyte|Children_(3_yrs) / Lineage, Cell type, age group and donor | 2.74e-04 | 196 | 29 | 3 | cacd69be72e6167814f7adea7c5fa114f3103bbb | |
| ToppCell | COVID-19-lung-Macrophage_CD163hi_MERTKhi|COVID-19 / Disease (COVID-19 only), tissue and cell type | 2.74e-04 | 196 | 29 | 3 | 7026c1fc33425e5476063d17c79e4b79356a9e01 | |
| ToppCell | COVID-19-lung-Macrophage_metabolically_active|lung / Disease (COVID-19 only), tissue and cell type | 2.74e-04 | 196 | 29 | 3 | a753d76d764c181eecb0e17a794a2e7d0ff70136 | |
| ToppCell | Fetal_29-31_weeks-Immune-monocyte-D062|Fetal_29-31_weeks / Lineage, Cell type, age group and donor | 2.78e-04 | 197 | 29 | 3 | 8b9a88fb671d5c2b25d291c851e2b8a478f2610c | |
| ToppCell | Control-B_memory-3|Control / disease group and sub_cluster of B and Plasma cells(res = 0.5) | 2.78e-04 | 197 | 29 | 3 | b86385c6c1d52ef4e3d855004d77afab61556978 | |
| ToppCell | COVID-19-kidney-Macrophages|COVID-19 / Disease (COVID-19 only), tissue and cell type | 2.78e-04 | 197 | 29 | 3 | 3912301018d0863144dcfac8d1fa8adc081748d7 | |
| ToppCell | COVID-19-lung-Macrophage_LDB2hi_OSMRhi_YAP1hi|lung / Disease (COVID-19 only), tissue and cell type | 2.78e-04 | 197 | 29 | 3 | 3896729740d151f0eb845f1961c7b969bfbdd28d | |
| ToppCell | 10x5'-lymph-node_spleen-Lymphocytic_B|lymph-node_spleen / Manually curated celltypes from each tissue | 2.82e-04 | 198 | 29 | 3 | 1780fa1725a321041094e8c4430673c0a4f3d407 | |
| ToppCell | Control-Control-Lymphocyte-B-B_memory|Control / Disease, condition lineage and cell class | 2.86e-04 | 199 | 29 | 3 | 76976d5f79f324a6c488161847c50f207361d6c6 | |
| ToppCell | mild-B_memory|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 2.86e-04 | 199 | 29 | 3 | e6ac9a0959b0de2c6a99298feb7715aa80ade1dd | |
| ToppCell | COVID-19-COVID-19_Convalescent-Lymphocyte-B-B_memory|COVID-19_Convalescent / Disease, condition lineage and cell class | 2.86e-04 | 199 | 29 | 3 | 5bbda86486910d053ca51b9caee487d78f6462cb | |
| ToppCell | COVID-19-COVID-19_Mild-Lymphocyte-B-B_memory|COVID-19_Mild / Disease, condition lineage and cell class | 2.86e-04 | 199 | 29 | 3 | 54e392b4ebe601d4838739ff7de3ac6b2203c948 | |
| ToppCell | MS-Multiple_Sclerosis-Lymphocyte-B-B_memory|Multiple_Sclerosis / Disease, condition lineage and cell class | 2.86e-04 | 199 | 29 | 3 | ae2979c0d2711580863d3b751f6ff1e3abdfd90e | |
| ToppCell | COVID-19-COVID-19_Severe-Lymphocyte-B-B_memory|COVID-19_Severe / Disease, condition lineage and cell class | 2.86e-04 | 199 | 29 | 3 | 24c05faa825c9d55279956469862440f9914a280 | |
| ToppCell | Sepsis-URO-Lymphocyte-B-B_memory|URO / Disease, condition lineage and cell class | 2.86e-04 | 199 | 29 | 3 | 040b51911a5d3b2ddd15497af2cf0ced9f271fee | |
| ToppCell | Neuronal-Excitatory-eE(FEZF2_SLC17A7)-eE_2-SCUBE1|Neuronal / cells hierarchy compared to all cells using T-Statistic | 2.90e-04 | 200 | 29 | 3 | 012dd2180f6f596d6e55e864be2e62b53c15edb2 | |
| ToppCell | severe-B_naive|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 2.90e-04 | 200 | 29 | 3 | 0e86f52b6e146d9bbc728d8fb176fc2b53696558 | |
| Computational | Genes in the cancer module 162. | 2.58e-06 | 19 | 16 | 3 | MODULE_162 | |
| Computational | Genes in the cancer module 218. | 3.04e-06 | 20 | 16 | 3 | MODULE_218 | |
| Drug | sipatrigine | 9.88e-10 | 37 | 29 | 5 | CID000060803 | |
| Drug | gastrodin | 3.04e-07 | 11 | 29 | 3 | CID000115067 | |
| Drug | 5-mm AI | 4.06e-07 | 12 | 29 | 3 | CID000131575 | |
| Drug | diphenyl sulfide | 6.70e-07 | 14 | 29 | 3 | CID000008766 | |
| Drug | Desvenlafaxine | 1.57e-06 | 2 | 29 | 2 | DB06700 | |
| Drug | Milnacipran | 1.57e-06 | 2 | 29 | 2 | DB04896 | |
| Drug | Amineptine | 1.57e-06 | 2 | 29 | 2 | DB04836 | |
| Drug | norcepharadione B | 1.57e-06 | 2 | 29 | 2 | CID000189168 | |
| Drug | Protriptyline | 1.57e-06 | 2 | 29 | 2 | DB00344 | |
| Drug | aristolactam AII | 1.57e-06 | 2 | 29 | 2 | CID000148657 | |
| Drug | Atomoxetine | 1.57e-06 | 2 | 29 | 2 | DB00289 | |
| Drug | alkosin | 1.57e-06 | 2 | 29 | 2 | CID005488638 | |
| Drug | nisoxetine | 1.57e-06 | 2 | 29 | 2 | ctd:C011386 | |
| Drug | piperolactam A | 1.57e-06 | 2 | 29 | 2 | CID003081016 | |
| Drug | 1,3-dipropylxanthine | 2.30e-06 | 74 | 29 | 4 | CID000169317 | |
| Drug | D-161 compound | 4.70e-06 | 3 | 29 | 2 | ctd:C532102 | |
| Drug | RTI-219 | 4.70e-06 | 3 | 29 | 2 | CID010524711 | |
| Drug | Mazindol | 4.70e-06 | 3 | 29 | 2 | DB00579 | |
| Drug | Dexmethylphenidate | 4.70e-06 | 3 | 29 | 2 | DB06701 | |
| Drug | Methylphenidate | 4.70e-06 | 3 | 29 | 2 | DB00422 | |
| Drug | Duloxetine | 4.70e-06 | 3 | 29 | 2 | DB00476 | |
| Drug | 2-(4-bromo-2,5-dimethoxyphenyl)ethylamine | 4.70e-06 | 3 | 29 | 2 | ctd:C079321 | |
| Drug | 5-(2-aminopropyl)benzofuran | 4.70e-06 | 3 | 29 | 2 | ctd:C000608250 | |
| Drug | 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone | 4.70e-06 | 3 | 29 | 2 | ctd:C569113 | |
| Drug | 1-phenyl-2-(1-pyrrolidinyl)-1-pentanone | 4.70e-06 | 3 | 29 | 2 | ctd:C000592273 | |
| Drug | 4-methoxymethamphetamine | 4.70e-06 | 3 | 29 | 2 | ctd:C060169 | |
| Drug | difluoropine | 4.70e-06 | 3 | 29 | 2 | CID000190851 | |
| Drug | 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine | 4.70e-06 | 3 | 29 | 2 | ctd:C554181 | |
| Drug | Venlafaxine | 4.70e-06 | 3 | 29 | 2 | DB00285 | |
| Drug | 2-(4-bromo-2,5-dimethoxyphenyl)-N-((2-methoxyphenyl)methyl)ethanamine | 4.70e-06 | 3 | 29 | 2 | ctd:C000595926 | |
| Drug | 4-fluoroamphetamine | 4.70e-06 | 3 | 29 | 2 | ctd:C040639 | |
| Drug | 1,4-diazabicyclo[3.3.1]nonane | 4.70e-06 | 3 | 29 | 2 | CID015140257 | |
| Drug | Sibutramine | 4.70e-06 | 3 | 29 | 2 | DB01105 | |
| Drug | calcium carbonate | 5.35e-06 | 203 | 29 | 5 | CID000010112 | |
| Drug | His-pro-dkp | 8.15e-06 | 31 | 29 | 3 | CID000065137 | |
| Drug | 3-aminopropylphosphinic acid | 8.99e-06 | 32 | 29 | 3 | CID006335948 | |
| Drug | AC 110 | 9.38e-06 | 4 | 29 | 2 | CID000022860 | |
| Drug | 4-(4-Chlorophenyl)piperidine | 9.38e-06 | 4 | 29 | 2 | CID001203613 | |
| Drug | [18f]fmener-d2 | 9.38e-06 | 4 | 29 | 2 | CID006914301 | |
| Drug | Fluorescent Dyes | 9.38e-06 | 4 | 29 | 2 | ctd:D005456 | |
| Drug | indatraline | 9.38e-06 | 4 | 29 | 2 | ctd:C418119 | |
| Drug | butriptyline | 9.38e-06 | 4 | 29 | 2 | CID000021771 | |
| Drug | Biogenic Monoamines | 9.38e-06 | 4 | 29 | 2 | ctd:D015306 | |
| Drug | Chlorpheniramine | 9.38e-06 | 4 | 29 | 2 | DB01114 | |
| Drug | almagel | 1.56e-05 | 5 | 29 | 2 | CID003080942 | |
| Drug | [11c]afa | 1.56e-05 | 5 | 29 | 2 | CID005352128 | |
| Drug | [11c]afm | 1.56e-05 | 5 | 29 | 2 | CID005352125 | |
| Drug | Phentermine | 1.56e-05 | 5 | 29 | 2 | DB00191 | |
| Drug | lortalamine | 1.56e-05 | 5 | 29 | 2 | CID000051047 | |
| Drug | [11c]afe | 1.56e-05 | 5 | 29 | 2 | CID005732447 | |
| Drug | doxepin | 1.78e-05 | 40 | 29 | 3 | CID000003158 | |
| Drug | desvenlafaxine | 1.92e-05 | 41 | 29 | 3 | CID000125017 | |
| Drug | AC1L9NDJ | 2.34e-05 | 6 | 29 | 2 | CID000449667 | |
| Drug | 3,4-dihydroquinazoline | 2.34e-05 | 6 | 29 | 2 | CID000583065 | |
| Drug | 3 MMA | 2.34e-05 | 6 | 29 | 2 | CID000130136 | |
| Drug | Mianserin | 2.34e-05 | 6 | 29 | 2 | DB06148 | |
| Drug | alpha-sialylcholesterol | 2.34e-05 | 6 | 29 | 2 | CID000133976 | |
| Drug | Clomipramine | 2.34e-05 | 6 | 29 | 2 | DB01242 | |
| Drug | Escitalopram | 2.34e-05 | 6 | 29 | 2 | DB01175 | |
| Drug | maprotiline | 2.38e-05 | 44 | 29 | 3 | CID000004011 | |
| Drug | amoxapine | 2.72e-05 | 46 | 29 | 3 | CID000002170 | |
| Drug | pseudoisocyanin | 3.28e-05 | 7 | 29 | 2 | CID000075462 | |
| Drug | oracaine | 3.28e-05 | 7 | 29 | 2 | CID000004065 | |
| Drug | 3,4-Methylenedioxymethamphetamine | 3.28e-05 | 7 | 29 | 2 | DB01454 | |
| Drug | MMDA | 3.28e-05 | 7 | 29 | 2 | DB01442 | |
| Drug | Pseudoephedrine | 3.28e-05 | 7 | 29 | 2 | DB00852 | |
| Drug | APMPA | 3.28e-05 | 7 | 29 | 2 | CID000512300 | |
| Drug | AC1Q5UBL | 3.40e-05 | 146 | 29 | 4 | CID000005466 | |
| Drug | Amoxapine | 4.37e-05 | 8 | 29 | 2 | DB00543 | |
| Drug | RTI-121 | 4.37e-05 | 8 | 29 | 2 | CID000122190 | |
| Drug | AC1L1GIZ | 4.37e-05 | 8 | 29 | 2 | CID000003703 | |
| Drug | Cocaine | 4.37e-05 | 8 | 29 | 2 | DB00907 | |
| Drug | Paroxetine | 4.37e-05 | 8 | 29 | 2 | DB00715 | |
| Drug | Octopamine | 4.37e-05 | 8 | 29 | 2 | ctd:D009655 | |
| Drug | phenethylamine | 5.61e-05 | 9 | 29 | 2 | ctd:C029261 | |
| Drug | Tramadol | 5.61e-05 | 9 | 29 | 2 | DB00193 | |
| Drug | Nefazodone | 5.61e-05 | 9 | 29 | 2 | DB01149 | |
| Drug | xylamine | 5.61e-05 | 9 | 29 | 2 | CID000005706 | |
| Drug | nortriptyline | 5.76e-05 | 59 | 29 | 3 | CID000004543 | |
| Drug | gabapentin | 6.02e-05 | 169 | 29 | 4 | CID000003446 | |
| Drug | pyrrolidine-2,4-dicarboxylate | 6.36e-05 | 61 | 29 | 3 | CID000003868 | |
| Drug | hydride | 6.70e-05 | 835 | 29 | 7 | CID000000783 | |
| Drug | demethoxymitomycin A | 7.00e-05 | 10 | 29 | 2 | CID000037972 | |
| Drug | NSC671195 | 7.00e-05 | 10 | 29 | 2 | CID000122834 | |
| Drug | Methamphetamine | 7.00e-05 | 10 | 29 | 2 | DB01577 | |
| Drug | smilageninoside | 7.00e-05 | 10 | 29 | 2 | CID000197391 | |
| Drug | 2-hydroxydesipramine | 7.00e-05 | 10 | 29 | 2 | CID000121249 | |
| Drug | methcathinone | 7.00e-05 | 10 | 29 | 2 | CID000001576 | |
| Drug | NO-711 | 8.05e-05 | 66 | 29 | 3 | CID000004515 | |
| Drug | [11c]dasb | 8.55e-05 | 11 | 29 | 2 | CID000656408 | |
| Drug | Imipramine | 8.55e-05 | 11 | 29 | 2 | DB00458 | |
| Drug | 4-hydroxy-3-methoxymethamphetamine | 8.55e-05 | 11 | 29 | 2 | CID003081137 | |
| Drug | Trimipramine | 8.55e-05 | 11 | 29 | 2 | DB00726 | |
| Drug | leys | 8.55e-05 | 11 | 29 | 2 | CID000484683 | |
| Drug | N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine | 9.20e-05 | 69 | 29 | 3 | CID000003172 | |
| Drug | baclofen | 9.67e-05 | 191 | 29 | 4 | CID000002284 | |
| Drug | 1-4a | 1.00e-04 | 71 | 29 | 3 | CID000657007 | |
| Drug | creatine | 1.01e-04 | 193 | 29 | 4 | CID000000586 | |
| Drug | Nortriptyline | 1.03e-04 | 12 | 29 | 2 | DB00540 | |
| Drug | FP-CIT | 1.03e-04 | 12 | 29 | 2 | CID000122197 | |
| Disease | familial hemiplegic migraine 1 (implicated_via_orthology) | 2.60e-06 | 3 | 28 | 2 | DOID:0111181 (implicated_via_orthology) | |
| Disease | migraine (implicated_via_orthology) | 5.20e-06 | 4 | 28 | 2 | DOID:6364 (implicated_via_orthology) | |
| Disease | Depressive Disorder, Treatment-Resistant | 8.67e-06 | 5 | 28 | 2 | C2063866 | |
| Disease | hereditary ataxia (implicated_via_orthology) | 1.82e-05 | 7 | 28 | 2 | DOID:0050951 (implicated_via_orthology) | |
| Disease | Recurrent depression | 3.11e-05 | 9 | 28 | 2 | C0221480 | |
| Disease | hyperinsulinism (biomarker_via_orthology) | 9.05e-05 | 15 | 28 | 2 | DOID:2018 (biomarker_via_orthology) | |
| Disease | Bipolar Disorder | 1.02e-03 | 477 | 28 | 4 | C0005586 | |
| Disease | Seizures | 1.14e-03 | 218 | 28 | 3 | C0036572 | |
| Disease | Manic | 2.49e-03 | 78 | 28 | 2 | C0338831 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| CFEAGIKIVALGFIF | 136 | Q15878 | |
| KALFVIVGLLTGCYF | 111 | Q9UF47 | |
| YFIGIFCFEAGIKII | 136 | Q00975 | |
| FCFEAGIKIIALGFV | 141 | Q00975 | |
| KVVFGLFFLGAILCL | 181 | Q86V24 | |
| LSKLGFEIVGYGCSI | 566 | P48200 | |
| CGVVLIISGIYLFIG | 426 | P53985 | |
| FFSYGIVVGLGCGLL | 106 | Q7RTY1 | |
| IGGLFPGTKYCFEIV | 506 | Q12913 | |
| FCQVGLGLELVKGYT | 346 | Q8N8M0 | |
| ASIDKIFGIIGCGYF | 2601 | Q96JB1 | |
| VGGKIFLIFYGLVGC | 121 | Q9HB14 | |
| LIYCLGVVFFKSDGI | 186 | Q15546 | |
| AVITVILGCLKIGYF | 141 | Q7RTM1 | |
| ILGCLKIGYFIGFSE | 146 | Q7RTM1 | |
| YNGKLYVFGGVCVIL | 486 | Q96M94 | |
| ICDPGYLLVGKGFIF | 1876 | P17927 | |
| YLLVGKGFIFCTDQG | 1881 | P17927 | |
| VLAGACFFLVLKYRG | 261 | P38484 | |
| FGDFIIFLGKVLVVC | 531 | Q8N4M1 | |
| IFLGKVLVVCFTVFG | 536 | Q8N4M1 | |
| GILKGYIIRYCLAGL | 721 | Q58EX2 | |
| GFGCFTGALLVKLVY | 476 | A6NIM6 | |
| GLTAYFGLLEICGVK | 126 | Q14914 | |
| GKGAFFCDLVLIYLI | 326 | Q93086 | |
| CPFFKGVGYAVILIA | 131 | P23975 | |
| AKVAYPLGLCVGVFI | 41 | O75354 | |
| FGIIILFYCAIIGGK | 116 | Q86UD5 | |
| LFYCAIIGGKLLGLI | 121 | Q86UD5 | |
| PGICAGIFIFFLIKY | 521 | P48066 | |
| YFLVGAGAIGCELLK | 471 | P22314 | |
| LLGYGLFGHCIVLFI | 221 | Q9GZM5 | |
| PIFKGIGYAICIIAF | 156 | P31645 | |
| FFTIVGLLFAGKVCL | 151 | Q8NHV5 |